Dr. Blum has spent decades advancing innovations, setting strategic visions and translating research concepts into viable commercial product opportunities with demonstrated success in the regen med and biotherapeutics space. As Co-founder of Humacyte, Blum spent nearly 20 yrs leading the development, management, and execution of a commercial scale bioengineering platform, eventually transitioning the start-up to a public company in 2021. She serves as an Executive in Residence at the North Carolina Biotech Center where she provides entrepreneurial mentoring and coaching for the early-stage companies in the Center’s loan portfolio. Blum also sits on the Board of Directors of inSoma Bio. Dr. Blum received her doctorate in Molecular Biology from Loyola University Chicago with a focus in cardiovascular gene therapy in 2003, and completed her BS at Carthage College in Wisconsin in 1998.